Combined Therapy with Cytokine-Induced Killer Cells and Oncolytic Adenovirus Expressing IL-12 Induce Enhanced Antitumor Activity in Liver Tumor Model

Zhi Yang1*, Qianzhen Zhang1*, Ke Xu1*, Juanjuan Shan1, Junjie Shen1, Limei Liu1, Yanmin Xu1, Feng Xia2, Ping Bie2, Xia Zhang1, Youhong Cui1, Xiu-wu Bian1, Cheng Qian1*

1 Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China, 2 Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China

Abstract

Both adoptive immunotherapy and gene therapy hold a great promise for treatment of malignancies. However, these strategies exhibit limited anti-tumor activity, when they are used alone. In this study, we explore whether combination of cytokine-induced killer (CIK) adoptive immunotherapy with oncolytic adenovirus-mediated transfer of human interleukin-12 (hIL-12) gene could induce the enhanced antitumor potency. Our results showed that oncolytic adenovirus carrying hIL-12 (AdCN205-IL12) could produce high levels of hIL-12 in liver cancer cells, as compared with replication-defective adenovirus expressing hIL-12 (Ad-IL12). AdCN205-IL12 could specifically induce cytotoxicity to liver cancer cells. Combination of CIK cells with AdCN205-IL12 could induce higher antitumor activity to liver cancer cells in vitro than that induced by either CIK or AdCN205-IL12 alone, or combination of CIK and control vector AdCN205-GFP. Furthermore, treatment of the established liver tumors with the combined therapy of CIK cells and AdCN205-IL12 resulted in tumor regression and long-term survival. High level expression of hIL-12 in tumor tissues could increase traffic of CIK cells to tumor tissues and enhance their antitumor activities. Our study provides a novel strategy for the therapy of cancer by the combination of CIK adoptive immunotherapy with oncolytic adenovirus-mediated transfer of immune stimulatory molecule hIL-12.

Introduction

As malignant diseases, liver cancer still holds a very high mortality rate despite of progression in the cutting edge medical technology. Recently, the application of cell-based immunotherapy for the treatment of malignant tumors has achieved encouraging results. Various types of immune cells have been used, including dendritic cells, lymphokine activated killer cells, natural killer cells, cytotoxic T cells, and cytokine-induced killer (CIK) cells [1,2,3,4,5]. Among them, ex vivo expanded CIK cells with both NK and T cell properties exhibit the most therapeutic effect in different experimental tumor models [6,7,8]. These cells are generated from peripheral blood mononuclear cells (PBMCs) by the sequential addition of interferon-γ (IFN-γ), anti-CD3 antibody, interleukin-1α and interleukin-2, and represented as heterogeneous cell populations including CD3+CD56+ cells with high antitumor activity [6]. Clinical studies indicated that therapy with CIK cells alone exhibited minor response in patients with high tumor burden [9]. But as an adjuvant immunotherapy, CIK cells might prevent recurrence and improve quality of life and progression-free survival rates [9,10].

To improve the therapeutic effect, the combined treatment strategy was suggested future direction [11,12,13]. Gene therapy has emerged as a powerful tool to regulate biological functions in diseased tissues and to treat cancers [14,15]. Oncolytic viruses not only have capacity to express therapeutic genes in tumor cells but also can be used as a direct tumor-destruction medicament. For safety, oncolytic viral replication must be controlled strictly within tumor cells. Thus, the different types of viruses have been genetically modified, including vaccinia, adenovirus, herpes simplex virus type I, reovirus and Newcastle disease virus [16,17,18,19,20]. One of the common strategies used to design oncolytic adenoviruses is to modify adenoviral E1A protein. The CR2 region of adenoviral E1A binds to retinoblastoma protein (RB), and the RB-related proteins which regulate the E2F family of transcription factors, and induces quiescent cells to enter S-phase. Since the tumor cells often have dysfunctional RB, and uncontrolled cell cycle, deletion of CR2 region allows this engineered adenovirus to selectively replicate in tumor cells but not in quiescent normal cells [21,22]. We have constructed several conditionally replicative adenovirus systems which viral replication was only occurred in primary tumors with high expression of hTERT and abnormal cell cycle checkpoint [22,23]. However, among...
these oncolytic adenoviruses, therapeutic genes were controlled by exogenous constitutive promoters. Thus, expression of therapeutic genes in normal tissue may induce undesired effect even if the virus does not replicate [24]. To overcome this limitation, we have developed the AdCN205 system which therapeutic gene expression is controlled by adenovirus E3 endogenous promoter. We have proven that this vector could express therapeutic gene in a predictable and safe manner [25].

Cytokines were reported to enhance CIK proliferation and antitumor efficacy in ex vivo culture or in vivo combined administration [5, 26, 27]. Our previous studies have indicated that interleukine-12 (IL-12) based gene therapy exerted strong antitumor activity in preclinical tumor models and human clinical trials [28, 29, 30]. Recently, Helms et al. showed that combination of CIK cells with IL-12 immunotherapy resulted in increased efficacy in a preclinical breast cancer model [26]. In the current study, we explore whether the enhanced antitumor activity can be achieved by the combination of adoptive immunotherapy of CIK cells with oncolytic adenovirus expressing hIL-12 (AdCN205-IL12). Our data indicate that combined therapy with CIK cells and oncolytic adenovirus expressing hIL-12 can induce the enhanced antitumor activity.

Results

1. The Construction of AdCN205-IL12 Virus

Previously, we developed a double-controlled oncolytic adenovirus system, AdCN205, in which hTERT promoter was used to control the expression of CR2 deleted E1A region and the 6.7 K/ gp19K of E3 region were substituted by the exogenous genes [25]. This vector allows selective adenoviral replication in the tumor cells harboring overexpression of hTERT and dysfunction of RB. The exogenous genes in the vector controlled by the adenovirus endogenous E3 promoter are expressed in the tumor cells following virus replication. In the present study, we constructed AdCN205-IL12 by replacing GFP with hIL-12 gene. The structures of AdCN205-GFP, AdCN205-IL12 and Ad-IL12 were shown in Figure 1A.

2. Selective Replication and Gene Expression of Oncolytic Adenoviral Vectors in vitro

To show kinetics of hIL-12 expression in the cells after infection with AdCN205-IL12, we infected tumor (HuH-7) and normal (AKN-1) cells with AdCN205-IL12. Our data showed that hIL-12 was detectable at 6 h in tumor cells after infection. There was a steady increase of hIL-12 expression up to 48 hours, which was maintained at high level until 96 hours after infection (Figure 1B). In contrast, hIL-12 was undetectable in normal cells until 30 hours after infection and we could only detect extremely low level of hIL-12 after that (Figure 1B). However, similar kinetics and level of hIL-12 expression were found in both tumor and normal cells infected with replication defective adenoviral vector Ad-IL12, in which hIL-12 was controlled by cytomegalovirus promoter (Figure 1C). The expression level of hIL-12 was about 12 times higher in the tumor cells infected with AdCN205-IL12 than that infected with Ad-IL12, indicating that oncolytic adenoviral vector could efficiency expression transgene. To confirm the specific expression of transgene in cancer cells by our vector system, we further infected both cancer and normal cells with control vector AdCN205-GFP. As shown in the Figure 1D, the high level of GFP expression was only observed in tumor cells accompanied with cytopathic effect, and no or low GFP expression was observed in normal cells after infection with AdCN205-GFP. Furthermore, we found that both of AdCN205-IL12 and AdCN205-GFP could specifically replicate in tumor cells but not in normal cells (Figure 1E). These data indicated that the difference in the kinetics and level of transgene expression may be due to tumor specific viral replication induced by oncolytic adenoviral vectors.

3. Characteristics of CIK Cell Populations

Results from phenotypic analysis of the cultured CIK by flow cytometry were presented in Figure S1. After 14-days culture, the percentage of CD3/CD8 double-positive, CD3/CD4 double-positive, CD3/CD56 double-positive, CD4/CD25 double-positive, and NK2G2D positive cells was 69.2±4.75%, 12.13±5.30%, 25.48±4.77%, 3.38±0.83%, 83.5±3.87% in CIK cultures, separately. These data is consistent with previous report [27]. To test whether adenovirus type 5 could infect CIK cells, we infected CIK cells with Ad5-GFP virus at different MOI (1–100), which GFP gene expression were controlled by CMV promoter. After 40 hours, GFP expression was analyzed by flow cytometry. Results showed that no GFP expression was observed even at high MOI. However, chimeric adenovirus vector Ad5/11-GFP [31] could efficiently transduce CIK cells (Figure S2).

4. Cytotoxic Effects of CIK Cell and Oncolytic Adenoviral Vectors on Liver Tumor Cells in vitro

To investigate the antitumor ability of the oncolytic adenovirus with therapeutic gene IL-12, we performed cytotoxicity assay after infection with adenoviruses. As shown in Figure 2, replication-defective adenovirus Ad-IL12 did not induce cytotoxicity, whereas AdCN205-GFP or AdCN205-IL12 induced significant cytotoxicity to the tumor cells. The cytotoxic effect on the tumor cells had no obvious difference between AdCN205-GFP and AdCN205-IL12. In contrast, AdCN205-GFP, AdCN205-IL12, and Ad-IL12 did not induce any cytotoxicity to the normal cells. These results indicate that AdCN205-GFP and AdCN205-IL12 can selectively replicate in liver cancer cells to kill them and IL-12 gene does not exert direct biological effect on cancer cells in vitro.

To investigate the cytotoxicity of CIK and CIK combined with oncolytic adenoviral vectors on cancer cells, cytotoxicity assays were performed by treatment of cancer cells (HuH-7 and Hep3B) with CIK cells alone or with oncolytic adenoviral vectors. Since the presence of CIK cells in the assay may cause interference in conventional cell viability assay, we engineered cancer cells expressing luciferase reporter gene to monitor survival of cancer cells by measurement of luminescence intensity from the survived cancer cells. Our results showed that CIK cells could exert minor cytotoxic effect on the cancer cells when effector:target ratio was 10:1. AdCN205-GFP and AdCN205-IL12 induced cytotoxicity at time-dependent manner. The combination of CIK cells with oncolytic adenovirus showed stronger cytotoxicity than either of them used alone. Particularly, combination of CIK with AdCN205-IL12 could induce significant cytotoxicity to the cancer cells, as compared with combination of CIK cells with AdCN205-GFP (Figure 3).

5. Antitumor Activity of the Combined Therapy in the Animal Model with Established Tumor

To investigate the antitumor potency of CIK cells combined with oncolytic adenoviral vectors in vivo, we treated the established liver tumors (HuH-7) in the SCID mouse model by intratumoral injection of AdCN205-GFP, AdCN205-IL12 or PBS and intravenous injection of CIK cells or PBS. Our data showed that animals receiving PBS expressed progressive tumor growth. Treatment with AdCN205-GFP, AdCN205-IL12, and CIK resulted in minor inhibition of tumor growth (Figure 4A). The
combined CIK and AdCN205-GFP exhibited stronger antitumor activity than either of them used alone. In contrast, the combined treatment with CIK and AdCN205-IL12 significantly inhibited tumor growth, as compared with the combination of CIK with AdCN205-GFP ($p = 0.0032$; Figure 4A). Two of eight animals treated with CIK and AdCN205-IL12 had complete tumor regression, and this combined therapy resulted in long-term survival (Figure 4B). The log-rank statistical test showed that PBS group had significant difference with AdCN205-GFP group ($p = 0.009$), AdCN205-IL12 group ($p = 0.001$), CIK group ($p < 0.0001$), CIK plus AdCN205-GFP group ($p < 0.0001$) and CIK plus AdCN205-IL12 group ($p < 0.0001$). The other groups had no significant difference among groups.

Immunohistochemical detection of blood vessels in the tumor sections by anti-mouse CD34 antibody revealed that presented a mass of blood vessels in PBS or CIK group, whereas only few blood vessels which detected in AdCN205-GFP, AdCN205-IL12 or Ad-IL12 at the MOI of 10 respectively. At 48 hours after viral infection, cells and medium were harvested, and viral particles were released by three cycles of freezing and thawing. The viral titers were measured by using plaque assay of QuickTiter™ Adenovirus Titer Immunoassay Kit on HEK293 cells. The data was presented as the mean ± SD of three independent experiments.
significantly lower than tumors treated with PBS and CIK cells (Figure S3). Furthermore, we detected human CIK cells in tumors by immunohistochemical analysis using anti-human CD3 antibody. Our result showed that infiltration of human CIK was largely enhanced in the tumors treated with CIK combined with AdCN205-IL12 (Figure 5).

6. Therapeutic Gene Expression in the Tumors After Treatment

To investigate whether exogenous therapeutic gene could be expressed in the tumors in vivo, mice were sacrificed after 6 days of treatment. We found that GFP was highly expressed in the tumor...
sections from animals treated with AdCN205-GFP and CIK plus AdCN205-GFP, whereas expression of GFP was undetectable in liver tissues, which is the primary infected tissue for adenovirus (Figure 6A). Similarly, the expression of hIL-12 was detected only in the tumors from the animals treated with AdCN205-IL12 and CIK plus AdCN205-IL12, while the combined treatment of CIK and oncolytic adenoviral vectors did not reduce the expression of transgenes (Figure 6B). Immunohistochemistry analysis showed that adenovirus hexon protein could only be detected in the tumor but not in liver sections when treated with AdCN205-GFP, AdCN205-IL12 plus CIK or not (Figure 6A). Thus, treatment with CIK cells does not affect the specificity of oncolytic adenovirus replication.

Discussion

Adaptive immunotherapy with CIK cells has been proven to be effective and safe for the treatment of cancers in the preclinical and clinical studies [9,32]. It has been shown that therapy with CIK cells exerts antitumor activity with high efficiency in the prevention of tumor recurrence after surgical removal of primary tumors [9,33]. However, in the late stage of cancer patients,
response rate is low and the tumor volume reduction is hardly achieved, due to the high tumor burden and the presence of immunosuppressive environment [9]. To improve the curative effect, combined therapeutic strategies are recommended [26,34,35,36]. Thus, exploring a novel strategy for decreasing tumor volume and improving tumor immunity may benefit for the following CIK adaptive immunotherapy.

Gene therapy offers a new approach to treat cancer. Oncolytic virus-mediated gene therapy combines the advantages of both gene therapy and virotherapy, which can not only deliver the therapeutic gene into the tumor tissues, but also directly reduce the...
tumor burden by oncolytic effect [23,25]. After the oncolytic effect, the release of tumor antigens may provide an opportunity for antigen-presenting by APC cells to enhance the tumor immune response [37,38,39]. However, immunity against cancer is often limited by weak immunogenicity of tumor antigens. Thus, transfer of genes encoding immune stimulatory cytokines has been used with remarkable success to suppress cancer and enhance immunity both in the animal models and the clinical trials [30]. Among immune stimulatory cytokines, IL-12 exerts the most potent antitumor activity by inducing a Th 1 type of response, and activating NK and CTL cells. IL-12 also inhibits tumor neoangiogenesis [40,41] and enhances the expression of adhesion molecules on the endothelial cells, thereby facilitating the traffic of lymphocytes to the tumor. Recently, Helms et al. reported that IL-12 could improve recruitment of CIK cells and the increased antitumor activity could be achieved by combining IL-12 cytokine therapy with CIK based adoptive immunotherapy [26].

Figure 6. The expression of exogenous gene in tumor sections and liver tissues. (A). Histologic and fluorescence analysis of tumor and liver sections from mice treated with PBS (a, d, g and j), AdCN205-GFP (b, e, h and k), CIK plus AdCN205-GFP (c, f, i and l). a to c, GFP was observed by fluorescence microscopy in the tumor tissue treated with PBS, AdCN205-GFP, or CIK plus AdCN205-GFP. d to f, Immunohistochemical staining for adenoviral hexon protein on the tumor sections (brown staining). g to i, GFP was observed by fluorescence microscopy in liver tissues. j to l, Immunohistochemical staining for adenoviral hexon protein on the liver sections. Original magnification, 200×. (B). The expression of hIL-12 in tumor fraction. Tumor tissues collected at the day of 6 after treatment. The hIL-12 was detected by ELISA. The data was presented as the mean ± SD (n = 3 per group).

doi:10.1371/journal.pone.0044802.g006
In this study, we explored a new strategy for the therapy of liver cancer by combination of oncolytic adenovirus expressing hIL-12 with CIK adaptive immunotherapy. The basis of this strategy is that viral replication kills tumor cells and expresses hIL-12. Meanwhile hIL-12 strengthens antitumor activity by increasing traffic of CIK cell to tumor regions and cytotoxic effect of CIK cells. For this purpose, we firstly constructed oncolytic adenovirus expressing hIL-12. As expected, high level of hIL-12 could be expressed in the cancer cells and only low level of hIL-12 could be detected in the normal cells after infection with oncolytic adenovirus carrying hIL-12 gene. In contrast, our previous replication defective adenovirus construct carrying IL-12 gene [30] only expressed low level of IL-12 both in the cancer cells and normal cells. Thus, the oncolytic adenovirus expressing IL-12 can serve a better delivery system for cancer therapy. We further demonstrated that both AdCN205-GFP and AdCN205-IL12 could specifically replicate and induce comparable cytotoxicity in liver cancer cells, indicating that hIL-12 has no direct effect on cancer cells survival. However, if AdCN205-IL12 was combined with CIK cells, the enhanced antitumor effect was observed.

Furthermore, this dramatic antitumor activity was also observed in an animal model with the established liver tumors. Complete tumor remission was observed in two of eight mice treated with the combination of CIK with AdCN205-IL12. And the long term survival was achieved by this therapy. The efficacy of combined treatment was superior to other tested treatment regimens including AdCN205-IL12 and CIK administered separately. Although the tumor remission was not observed in the tumor-bearing animals treated with CIK combined with AdCN205-GFP, tumor suppression and animal survival was significantly improved, as compared with CIK or AdCN205-GFP treatment alone, implying that the oncolytic virus therapy and CIK immunotherapy have enhanced effects, and therapeutic gene IL-12 can further amplify these effects.

Our previous preclinical and clinical cancer gene therapy studies using hIL-12 indicated that hIL-12 could induce antitumor activity by reducing tumor angiogenesis and increasing lymphocyte traffic to tumor tissue overexpressing adhesion molecules [30]. In this study, we found that tumors treated with AdCN205-IL12 alone or combined with CIK resulted in obvious decrease in the blood vessel destiny. In addition, the increased lymphocyte infiltration was found in the tumor-bearing animals after treatment with AdCN205-IL12 and CIK cells, indicating that high level of hIL-12 expression in the tumor tissue can enhance traffic of CIK cells to tumor tissue and increase antitumor activity of CIK cells.

Although IL-12 has been reported to have the lethal toxicity by intravenous administration in a phase II clinical trial [42,43], no obvious side effect was observed in the clinical application of IL-12 expressing adenovirus vector by intratumor injection [30]. For the avoidance of IL-12 gene expression in the non-tumor tissue, we employed the AdCN205 system vector to allow hIL-12 expression only in those tumor cells with high level hTERT expression and dysfunctional RB [25]. Thus, this system further guarantees safety of using IL-12 for cancer therapy.

In summary, we provide a novel strategy for cancer treatment by combination of CIK adoptive immunotherapy with oncolytic adenovirus expressing immune stimulatory molecule hIL-12.

Materials and Methods

1. Ethics Statement

We didn’t use of any non-human primates in the research. The SCID mice in this research were obtained from the Third Military Medical University and maintained at pathogen-free conditions. All procedures were done according to protocols approved by the Institutional Review Board of the Southwest Hospital, Third Military Medical University and conformed to the NIH guidelines on the ethical use of animals.

2. Generation of CIK Cells

Human peripheral blood mononuclear cells (PBMCs) were obtained from health donors with written informed consent from all persons according to protocols approved by the Institutional Review Board of the Southwest Hospital, Third Military Medical University. CIK cells were generated as described previously [27]. Briefly, human PBMCs were cultured in RPMI 1640 medium (Gibco, Inc) containing 10% fetal calf serum (Gibco Inc), 25 mM HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin. Human recombinant IFN-γ (Peprotech, Inc) were added at 1000 U/ml on day 0. After 24 hours of incubation, 50 ng/ml of antibody against CD3 (cBiobioscience, Inc), 100 U/ml IL-12 (Invitrogen, Inc) and 300 U/ml IL-2 (Peprotech, Inc) were added. Cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ and subcultured every 3 days in fresh complete medium and 300 U/ml IL-2 at 3 × 10⁶ cells/ml. The cells were cultured until 14 days to obtain CIK cells.

3. Cell Lines and Cell Culture

Human hepatocellular carcinoma (HCC) cell lines Hep3B (HBs⁺/undetected Rb), were purchased from American Tissue Culture Collection (ATCC, Manassas, VA, USA), BEL7404 (HBs⁺/Rb⁺), SMMC7721 (HBs⁺/Rb⁺), MHCC97H (HBs⁺/Rb⁺), hyperphosphorylated) and HuH7 (HBs⁺/Rb⁺ hyperphosphorylated) [44,45,46] were purchased from the Shanghai Cell Collection, China. Human normal liver cell line AKN-1 (HBs⁺/Rb⁺) was obtained from Pro. Stephen C. Strom [47]. HEK293 was obtained from Microbix Biosystems Inc (Etobicoke, ON, Canada). Cells were cultured in Dulbecco’s modified essential medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Inc), 4 mM glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin at 37°C in a humidified atmosphere with 5% CO₂. The expression level of hIL12 in HCC and normal cell lines was measured by qRT-PCR. Our result showed that HCC cell lines expressed higher level of hTERT than normal liver cell line (Figure S4).

4. Virus Construction

Human hIL12-p40-Δp35 cDNA was obtained by PCR from the Ad-IL12 vector described before [30]. The amplification for hIL12-p40 was done with forward (5’-CCATGGGTACGACGAGACTCAG-3’) and reverse (5’-GATCAACCTCAGTTGTTTTTCA-3’) primers. The amplification for hIL12-Δp35 was done with forward (5’-CCATGGCATGCTCGAGGACCAGAT-3’) and reverse (5’-GCCGCGCGCGCAGGGCAGCACA-3’) primers. The PCR fragments were cloned to pMD-18-T-hIL12-p40-Δp35 after digested by XhoI. hIL12-p40-Δp35 gene was excised from pMD-18-T-hIL12-p40-Δp35 with NdeI and KpnI and clone to pcDNA4. The construction of pcDNA5-hIL12-p40-Δp35 was generated according to the standard protocol described before [25]. Homologous recombination between pcDNA5-hIL12-p40-Δp35 and pcDNA3 plasmids carrying oncolytic adenoviral backbone was done in E.coli strain, Bj5183 to create pCN205-hIL12-p40-Δp35 (pCN205-IL12). Viral particles were produced in HEK293 cells by transfection with PacI-digested pCN205-GFP and pCN205-IL12 to obtain recombinant AdCN205-GFP and AdCN205-IL12. All viruses were propagated and purified by CsCl gradient centrifugation.
5. RNA Purification and Reverse Transcription PCR

Total RNA was purified from cultured cells with the RNAiso Plus reagent (TaKaRa, Shiga, Japan), and 2 μg of total RNA were reverse-transcribed with PrimeScript RT reagent Kit (TaKaRa, Shiga, Japan). 2 μl of the diluted RT reaction product was added in the SYBR Premix Ex Taq II (TaKaRa, Shiga, Japan) RT-PCR reaction mixture, and detected by the CFX96™ Real-Time PCR Detection System (Bio-Rad, Inc.). The PCR primers for hTERT are forward (5′GGCTGTGGCACAAGCATTTC3′) and reverse (5′AGGGCTGCTGTTGTCGCT3′), for GAPDH are forward (5′TTGCGAGTGGCAAAAGTGGA3′) and reverse (5′CGTGGTTCAAGCCCATCGA3′).

6. In vitro Transduction Studies

For adherent cells, the day before infection, 3 × 10⁵ cells per well (24-well plate) were seeded. The next day, attached cells were counted and viruses were added at the multiplicities of infection (MOI) indicated in the figure legends in 1 ml of growth medium. Cells were incubated with virus for 6 hours, then washed twice with PBS and incubated at 37°C. Percentages of GFP-positive cells and mean fluorescence were determined by flow cytometry.

7. Viral Progeny Assay

To determine viral replication capacity, tumor or normal cells were infected with Ad-IL12, AdCN205-GFP, and AdCN205-IL12 at the multiplicity of infection of 10. Adenoviruses were removed after 6 hours of infection. The cells were washed twice with PBS and cultured in the completed medium at 37°C. After 48 hours, the cells were collected by trypsinization and centrifugation and then lysed with three cycles of freeze thawing. After centrifugation, the supernatant was collected. Viral titers were determined by adenovirus Titer Immunoassay Kit on HEK293 cells.

8. Cytotoxicity Assay

Cells were plated in 96-well plates and treated with various adenoviruses. At the indicated times, medium was removed and changed to fresh medium containing 10 μl CCK-8 (Cell counting kit-8, Dojindo). Cells were incubated at 37°C for 2 hours. Absorbance was read on a spectral Scanning Multimode Reader (Varioskan Flash, Thermo Scientific) at 450 nm. To determine the CIK-mediated cellular cytotoxicity, tumor cell lysis by effector cells was assessed by measurement of the luciferase activity of surviving target cells. Target cells expressing luciferase were plated into black-walled 96-well plates at 1 × 10⁴ cells/well. Effector cells were then added at effector-to-target ratios 10 to 1; wells representing all ratios of cells and target cells only wells were plated in triplicate and incubated for 24 to 72 hours at 37°C, 5% CO₂. The Luciferase Assay Reagent was then added to each well (Promega inc) and light output measured on luminometric spectral reader (Varioskan Flash, Thermo Scientific). Percent cytotoxicity was then determined relative to control wells.

9. Immunohistochemistry, Fluorescence, and Flow Cytometry Studies

Immunohistochemistry: Deparaffinanged tumor sections were treated with rabbit anti-human CD3 polyclonal antibody (1:50; Abcam), rabbit anti-human CD34 monoclonal antibody (1:200; Abcam), goat anti-Adenovirus Hexon polyclonal (diluted 1:500; Santa Cruz Biotechnology). After incubation with anti-rabbit or anti-goat secondary antibody, gene expression was detected with 3,3-diaminobenzidine (Sigma) by enhancement with an avidin-biotin reaction ABC kit (Vector Laboratories). The slides were then counterstained with hematoxylin. Fluorescence: The green fluorescence of the AdCN205-GFP infected cells was assayed using a 530-nm/30-nm bandpass filter after illumination with an argon ion laser tuned at 488 nm (AXIO OBSERVER A1, Carl Zeiss, Inc). Tumor sections infected by AdCN205-GFP assayed by a fluorescence stereo microscopy (SZX10, Olympus, Inc). Flow cytometry: Cells were obtained from CIK cultures for phenotype analysis with appropriate monoclonal antibodies, including mouse anti-human CD3-FTTC (BD Biosciences, CA, USA), mouse anti-human CD4-PE (BD Biosciences, CA, USA), mouse anti-human CD8-PE-Cy5 (BD Biosciences, CA, USA), mouse anti-human CD314-PE (BD Biosciences, CA, USA). 1 × 10⁵ CIK cells were washed once with PBS containing 1% bovine serum albumin (BSA) and resuspended in 100 μl of PBS/BSA buffer. The cells were incubated with various conjugated monoclonal antibodies for 20 minutes at 4°C, washed twice with PBS, and resuspended in 300 μl of PBS. Flow cytometric analysis was performed on a FACS Aria II flow cytometer (BD Biosciences, CA, USA).

10. Enzyme-linked Immunosorbent Assay

Detection of human IL-12 (P70) in the cell culture supernatant or tissues was performed by using an ELISA kit (R&D Systems) according to the manufacturer’s instruction.

11. In vivo Study of Anti-tumor Effect

Male SCID mice at 3 to 4 weeks of age were obtained from the Third Military Medical University and maintained at pathogen-free conditions. All procedures were done according to institutional guidelines and conformed to the NIH guidelines on the ethical use of animals. HuH-7 cells (1 × 10⁶) were injected s.c. into the flanks of mice. When the tumors reached to 100 to 150 mm³, the animals were randomized into six groups, and treated with either PBS or 2 × 10⁷ IFU of vectors (AdCN205-GFP or AdCN205-IL12) by intratumoral injection or 1 × 10⁹ CIK cells by intravenous injection, or intravenous injection 1 × 10⁷ CIK combined with intratumoral injection of 2 × 10⁹ IFU vectors (CIK combined with AdCN205-GFP or CIK combined with AdCN205-IL12). Tumors were measured twice weekly and tumor volume was calculated according to the following equation: V (mm³) = (width² x length)/2. Animal death was documented. Animals were sacrificed and were considered as death, when the diameter of the tumor reached 17 mm or when mean diameter was >15 mm.

12. Statistical Analysis

All in vitro experiments were performed at least three times. The statistical significance was calculated by analysis of variance when
more than two groups were compared or by student t-test when only two groups were compared. *p<0.05 and **p<0.01. In vivo experiment was performed once with 8 animals in each group. The statistical significance of tumor growth curve was calculated by student t-test, and the statistical significance of survival curve was calculated by log-rank statistical test. *p<0.05 and **p<0.01.

Supporting Information

Figure S1 The phenotype of CIK cells. CIK cells were stained with various monoclonal anti-bodies as outlined above. The expression of the CD3, CD56, CD4, CD8, CD16, NKG2D, stained with various monoclonal anti-bodies as outlined above.

Figure S2 The infection of Ad5-GFP virus in CIK cells. The GFP positive rate was below 0.2% even in 100 MOI. Chimeric adenovirus vector Ad5/11-GFP used as a positive control. The data was presented as mean ± SD of three independent experiments. (TIF)

Figure S3 The vascular density in tumor. The vascular density was quantified by counting numbers of endothelial cells in 5 random fields per section at 200x magnification. The vascular density from PBS group has significant difference with that from AdCN205-GFP plus CIK (p = 0.045499) and AdCN205-IL12 plus CIK group (p = 0.033946). The vascular density from CIK group has significant difference with AdCN205-GFP plus CIK (p = 0.038171) and AdCN205-IL12 plus CIK group (p = 0.029449). (TIF)

Figure S4 The detection of hTERT expression in liver cancer and normal liver cell lines by real time PCR. The expression of hTERT gene of liver cancer cell lines (SMMC7721, BEL7404, MHCC97H, HuH-7 and Hep3B) and normal liver cell (AKN-1) was detected by real time PCR. (TIF)

Author Contributions

Conceived and designed the experiments: ZY CQ. Performed the experiments: ZY QZZ KX LML XYM. Analyzed the data: ZY JJS JJS FX PB YHC XWB. Contributed reagents/materials/analysis tools: ZY QZZ KX LML YHC XWB. Wrote the paper: ZY CQ NZ.

References

1. Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34: 324–331.
2. Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487–1489.
3. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299–308.
4. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, et al. (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487–1489.
5. Schneider-Wolf RI, Finke S, Trojeanek B, Denkena A, Leferova P, et al. (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81: 1009–1116.
6. Liu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687–1696.
7. Pevasa A, Bordei G, Pende D, Moretta L, Rambaldi A, et al. (2011) Dual functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood.
8. Nian M, Linn YC, Fook Chong S, Lim T, Chu S, et al. (2011) Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 39: 897–903 e891.
9. Hontsch A, Bock Y, Zhou H, Messmer D, Schneider-Wolf IG (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (RCC). J Cancer Res Clin Oncol 137: 305–310.
10. Li H, Wang C, Yu J, Gao S, Wei F, et al. (2009) Dendritic cell-activated cytokine-induced killer cell lines enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11: 1076–1083.
11. Pevasa A, Belussi C, Klein C, Rambaldi A, Golay J, et al. (2011) Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD50 antibodies. Blood 117: 310–318.
12. Jin J, Joo KM, Lee SJ, Jo MY, Kim Y, et al. (2011) Synergistic therapeutic effects of cytokine-induced killer cells and tenofovir disoproxil fumarate against glioblastoma. Oncol Rep 25: 33–39.
13. Zhou P, Liang P, Dong B, Yu X, Han Z, et al. (2011) Phase clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther 11: 450–456.
14. Sangro B, Prieto J (2010) Gene therapy for liver cancer: clinical experience and future prospects. Curr Opin Mol Ther 12: 361–369.
15. Alexander BL, Ali RR, Alkon EW, Rainbird JW, Braun S, et al. (2007) Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 14: 1439–1447.
16. Qian C, Sangro B, Prieto J (2002) New strategies to enhance gene therapy efficiency. Gastroenterology 123: 639–642.
17. Qian C, Liu XY, Prieto J (2006) Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 16: 182–188.
18. Kim D, Martuza RL, Zuechel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781–787.
19. McCormick F (2007) Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 7: 130–141.
20. He X, Liu J, Yang C, Su C, Zhou C, et al. (2011) 5/35 fiber-modified conditionally replicative adeno virus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum Gene Ther 22: 283–292.
21. Berk AJ (2005) Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673–7683.
22. Zhang W, Cai R, Lao J, Wang Y, Cai Q, et al. (2007) The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther 6: 1726–1732.
23. Cui Q, Jiang W, Wang Y, Le C, Lao J, et al. (2008) Transfer of suppressor of cytokine signalling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology 47: 105–112.
24. Papadakis ED, Nicklin SA, Baker AH, White SJ (2004) Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 4: 89–113.
25. Lao J, Xia Q, Zhang R, Le C, Zhang W, et al. (2008) Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res 14: 2450–2457.
26. Helms MW, Prechser JA, Gao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cytoskeleton Immunol 59: 1325–1334.
27. Finke S, Trojeanek B, Leferova P, Caiapai M, Wagner E, et al. (1998) Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther 5: 31–39.
28. Alves A, Ribeiro C, Machado S, Falcão M, et al. (2004) Adjuvant interleukin-12 gene therapy for the management of colorectal liver metastases. Cancer Gene Ther 11: 782–789.
29. Zahala M, Wang L, Hernandez-Aloceo R, Hillen W, Qian C, et al. (2004) Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. Cancer Res 64: 2799–2804.
30. Sangro B, Mazzolin G, Ruiz J, Herranz M, Quiroga J, et al. (2004) Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389–1397.
31. Yu L, Shimozato O, Li Q, Kawamura K, Ma G, et al. (2007) Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human digestive tumors. J Clin Oncol 22: 1389–1397.
32. Liu L, Zhang W, Qi X, Li H, Yu J, et al. (2012) Randomized Study of Autologous Cytokine-induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma. Clin Cancer Res.
33. Ma Y, Zhang Z, Tang L, Xu XC, Xie XM, et al. (2012) Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy.
34. Niu Q, Wang W, Li Y, Qin S, Wang Y, et al. (2011) Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemother-
apy in the treatment of advanced solid malignancies. Int Immunopharmacol 11: 449–456.

35. Jiang J, Xu N, Wu C, Deng H, Lu M, et al. (2006) Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26: 2237–2242.

36. Thorne SH, Negrin RS, Contag CH (2006) Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780–1784.

37. Hu W, Davis JJ, Zhu H, Dong F, Guo W, et al. (2007) Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 6: 1773–1779.

38. Li H, Zeng Z, Fu X, Zhang X (2007) Co-administration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res 67: 7850–7853.

39. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, et al. (2006) Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 13: 253–265.

40. Wong RJ, Chan MK, Yu Z, Ghosein RA, Ngai I, et al. (2004) Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10: 4509–4516.

41. Del Vecchio M, Rajetta E, Canova S, Lotze MT, Wesa A, et al. (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677–4683.

42. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, et al. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541–2548.

43. Sacco S, Heremans H, Echtenacher B, Buurman WA, Amraoui Z, et al. (1997) Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. Blood 90: 4473–4479.

44. Wang B, Xunsun, Liu JY, Yang D, Yang LL, et al. (2012) The Effect of Cell Cycle and Expression of Cyclin B1 and Cyclin C Protein in Hepatocellular Carcinoma Cell Line HepG2 and SMMC-7721 after of Silencing beta-Catenin Gene. Hepatogastroenterology 59: 515–518.

45. Kaino M (1997) Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J Gastroenterol 32: 40–46.

46. Liu LX, Lee NP, Chan VW, Xue W, Zender L, et al. (2009) Targeting cadherin-11 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 50: 1453–1463.

47. Nussler AK, Vergani G, Gollin SM, Dorko K, Morris SM Jr, et al. (1999) Isolation and characterization of a human hepatic epithelial-like cell line (AKN-1) from a normal liver. In Vitro Cell Dev Biol Anim 35: 190–197.